Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | IDE | P14735 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114924 | 1.00 | MEN1 (0.34) | MEN1MAPK10KMT2AHRH4BRD4 | |
| SCHEMBL22506323 | 0.93 | PSIP1 (0.36) | BRD4 | |
| SCHEMBL15342590 | 0.93 | PSIP1 (0.36) | BRD4 | |
| SCHEMBL15342181 | 0.90 | — | — | |
| SCHEMBL20101206 | 0.86 | CNR1 (0.31) | — | |
| SCHEMBL31114857 | 0.86 | CNR1 (0.31) | — | |
| SCHEMBL20101157 | 0.85 | PSD (0.30) | ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL31114889 | 0.85 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL15334414 | 0.84 | CYP3A4 (0.32) | — | |
| SCHEMBL15334410 | 0.84 | CYP3A4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078991-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10800772-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800772-B2 | Therapeutic compounds | NQO1, HAVCR2, CCR5 | MEN1 3124/4885MAPK10 1419/4885KMT2A 4385/4885 |
| US-20210078991-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MEN1 3124/4885MAPK10 1419/4885KMT2A 4385/4885 |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MEN1 3124/4885MAPK10 1419/4885KMT2A 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.